Vis enkel innførsel

dc.contributor.authorHilvo, Men_US
dc.contributor.authorMeikle, PJen_US
dc.contributor.authorPedersen, ERen_US
dc.contributor.authorTell, Grethe S.en_US
dc.contributor.authorDhar, Induen_US
dc.contributor.authorBrenner, Hen_US
dc.contributor.authorSchöttker, Ben_US
dc.contributor.authorLääperi, Men_US
dc.contributor.authorKauhanen, Den_US
dc.contributor.authorKoistinen, KMen_US
dc.contributor.authorJylhä, Aen_US
dc.contributor.authorHuynh, Ken_US
dc.contributor.authorMellett, NAen_US
dc.contributor.authorTonkin, AMen_US
dc.contributor.authorSullivan, DRen_US
dc.contributor.authorSimes, Jen_US
dc.contributor.authorNestel, Pen_US
dc.contributor.authorKoenig, Wen_US
dc.contributor.authorRothenbacher, Den_US
dc.contributor.authorNygård, Ottaren_US
dc.contributor.authorLaaksonen, Ren_US
dc.PublishedHilvo, Meikle, Pedersen, Tell GST, Dhar I, Brenner H, et al. Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.. Journal of Heart Failure. 2020;41:371-380eng
dc.description.abstractAims: Distinct ceramide lipids have been shown to predict the risk for cardiovascular disease (CVD) events, especially cardiovascular death. As phospholipids have also been linked with CVD risk, we investigated whether the combination of ceramides with phosphatidylcholines (PCs) would be synergistic in the prediction of CVD events in patients with atherosclerotic coronary heart disease in three independent cohort studies. Methods and results: Ceramides and PCs were analysed using liquid chromatography–mass spectrometry (LC-MS) in three studies: WECAC (The Western Norway Coronary Angiography Cohort) (N = 3789), LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) trial (N = 5991), and KAROLA (Langzeiterfolge der KARdiOLogischen Anschlussheilbehandlung) (N = 1023). A simple risk score, based on the ceramides and PCs showing the best prognostic features, was developed in the WECAC study and validated in the two other cohorts. This score was highly significant in predicting CVD mortality [multiadjusted hazard ratios (HRs; 95% confidence interval) per standard deviation were 1.44 (1.28–1.63) in WECAC, 1.47 (1.34–1.61) in the LIPID trial, and 1.69 (1.31–2.17) in KAROLA]. In addition, a combination of the risk score with high-sensitivity troponin T increased the HRs to 1.63 (1.44–1.85) and 2.04 (1.57–2.64) in WECAC and KAROLA cohorts, respectively. The C-statistics in WECAC for the risk score combined with sex and age was 0.76 for CVD death. The ceramide-phospholipid risk score showed comparable and synergistic predictive performance with previously published CVD risk models for secondary prevention. Conclusion: A simple ceramide- and phospholipid-based risk score can efficiently predict residual CVD event risk in patients with coronary artery disease.en_US
dc.publisherOxford University Presseng
dc.rightsAttribution-Non Commercial CC BY-NCeng
dc.titleDevelopment and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.en_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2019 The Authors
dc.source.journalJournal of Heart Failure

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-Non Commercial CC BY-NC
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-Non Commercial CC BY-NC